Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;11(5):1353.
doi: 10.3390/jcm11051353.

Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain)

Montse Gasol  1   2   3 , Noelia Paco  2 , Laura Guarga  2 , Josep Àngel Bosch  4 , Caridad Pontes  1   2   3 , Mercè Obach  2
Affiliations

Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain)

Montse Gasol et al. J Clin Med. .

Abstract

Early access to medicines allows the prescription of a medicine before it is available in the public formulary to patients with severe or rare diseases with high unmet needs who have no authorised therapeutic alternatives available. In this context, consistent decision making is difficult, and a systematic assessment procedure could be useful to tackle complex situations and guarantee the equity of medicines' access. A multidisciplinary panel (MP) conducted four workshops to develop an early access framework based on a reflective multiple criteria decision analysis (MCDA). A set of 12 criteria was agreed: eight quantitative (severity of disease, urgency, efficacy, safety, internal and external validity, therapeutic benefit and plausibility) and four qualitative (therapeutic alternative, existence of precedents, management impact and costs). Quantitative criteria were weighted using a five-point scale. The relative importance of quantitative criteria had mean weights from 4.7 to 3.6, showing its relevance in the decisions. The framework was tested using two case studies, and reliability was assessed by re-test. The re-test revealed no statistical differences, indicating the consistency and replicability of the framework developed. MCDA may help to structure discussions for heterogeneous treatment requests, providing predictability and robustness in decision making involving sensitive and complex situations.

Keywords: MCDA; assessment; drug policy; early access; multicriteria decision analysis; pharmaceuticals.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mean (SD) of relative importance rated by participants to final early access framework.
Figure 2
Figure 2
Relative importance according to professional profile.
Figure 3
Figure 3
Dupilumab for the treatment of a paediatric patient with severe atopic dermatitis: (a) value of contribution of quantitative criteria; (b) impact of qualitative criteria (percentage of members who assigned a favourable, neutral and unfavourable).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use. Springer; Berlin/Heidelberg, Germany: 2001. European Parliament. - DOI
    1. Henshall C., Mardhani-Bayne L., Frønsdal K.B., Klemp M. Interactions between Health Technology Assessment, Coverage, and Regulatory Processes: Emerging Issues, Goals, and Opportunities. Int. J. Technol. Assess. Health Care. 2011;27:253–260. doi: 10.1017/S0266462311000262. - DOI - PubMed
    1. Patil S. Early Access Programs: Benefits, Challenges, and Key Considerations for Successful Implementation. Perspect. Clin. Res. 2016;7:4. doi: 10.4103/2229-3485.173779. - DOI - PMC - PubMed
    1. Angelis A., Lange A., Kanavos P. Using Health Technology Assessment to Assess the Value of New Medicines: Results of a Systematic Review and Expert Consultation across Eight European Countries. Eur. J. Health Econ. 2018;19:123–152. doi: 10.1007/s10198-017-0871-0. - DOI - PMC - PubMed
    1. World Health Organization—WHO . Medicines Reimbursement Policies in Europe. Regional Office for Europe; Geneva, Switzerland: 2018.